| Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre L Hondebrink, JJ Nugteren-van Lonkhuyzen, D Van Der Gouwe, TM Brunt Drug and alcohol dependence 147, 109-115, 2015 | 118 | 2015 |
| Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? L Hondebrink, A Zwartsen, RHS Westerink Pharmacology & therapeutics 182, 193-224, 2018 | 76 | 2018 |
| Is the time right for in vitro neurotoxicity testing using human iPSC-derived neurons? AM Tukker, MW de Groot, FMJ Wijnolts, EEJ Kasteel, L Hondebrink, ... ALTEX-Alternatives to animal experimentation 33 (3), 261-271, 2016 | 75 | 2016 |
| Pharmacokinetics and pharmacodynamics of 3, 4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions SJ Rietjens, L Hondebrink, RHS Westerink, J Meulenbelt Critical reviews in toxicology 42 (10), 854-876, 2012 | 61 | 2012 |
| Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings L Hondebrink, AHA Verboven, WS Drega, S Schmeink, M De Groot, ... Neurotoxicology 55, 1-9, 2016 | 54 | 2016 |
| Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans JJ Nugteren-van Lonkhuyzen, AJHP van Riel, TM Brunt, L Hondebrink Drug and alcohol dependence 157, 18-27, 2015 | 51 | 2015 |
| Neurotoxicity screening of new psychoactive substances (NPS): effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA) A Zwartsen, L Hondebrink, RHS Westerink Neurotoxicology 66, 87-97, 2018 | 40 | 2018 |
| Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay A Zwartsen, AHA Verboven, RGDM van Kleef, FMJ Wijnolts, ... Toxicology in Vitro 45, 60-71, 2017 | 38 | 2017 |
| New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017 L Hondebrink, JJ Nugteren‐van Lonkhuyzen, CC Hunault, J van den Berg, ... Addiction 115 (4), 716-725, 2020 | 36 | 2020 |
| Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings A Zwartsen, T de Korte, P Nacken, DW de Lange, RHS Westerink, ... Journal of molecular and cellular cardiology 136, 102-112, 2019 | 36 | 2019 |
| Neuropharmacological characterization of the new psychoactive substance methoxetamine L Hondebrink, EEJ Kasteel, AM Tukker, FMJ Wijnolts, AHA Verboven, ... Neuropharmacology 123, 1-9, 2017 | 36 | 2017 |
| Fatalities, cerebral hemorrhage, and severe cardiovascular toxicity after exposure to the new psychoactive substance 4-fluoroamphetamine: a prospective cohort study L Hondebrink, JJ Nugteren–van Lonkhuyzen, SJ Rietjens, TM Brunt, ... Annals of emergency medicine 71 (3), 294-305, 2018 | 31 | 2018 |
| High concentrations of MDMA (‘ecstasy’) and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells L Hondebrink, J Meulenbelt, M Meijer, M van den Berg, RHS Westerink Neuropharmacology 61 (1-2), 202-208, 2011 | 26 | 2011 |
| Additive inhibition of human α1β2γ2 GABAA receptors by mixtures of commonly used drugs of abuse L Hondebrink, S Tan, E Hermans, RGDM van Kleef, J Meulenbelt, ... Neurotoxicology 35, 23-29, 2013 | 23 | 2013 |
| Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse L Hondebrink, J Meulenbelt, R van Kleef, M van Den Berg, ... Neurotoxicology 32 (6), 823-827, 2011 | 20 | 2011 |
| Hazard characterization of synthetic cathinones using viability, monoamine reuptake, and neuronal activity assays A Zwartsen, ME Olijhoek, RHS Westerink, L Hondebrink Frontiers in neuroscience 14, 9, 2020 | 19 | 2020 |
| Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic … A Zwartsen, L Hondebrink, RHS Westerink Neurotoxicology 74, 28-39, 2019 | 19 | 2019 |
| Synthetic cathinones and their potential interactions with prescription drugs RR Contrucci, TM Brunt, F Inan, EJF Franssen, L Hondebrink Therapeutic Drug Monitoring 42 (1), 75-82, 2020 | 18 | 2020 |
| Acute toxic effects related to 4-fluoroamphetamine CHW Wijers, RTH van Litsenburg, L Hondebrink, RJM Niesink, EA Croes The Lancet 389 (10069), 600, 2017 | 15 | 2017 |
| Amphetamine reduces vesicular dopamine content in dexamethasone‐differentiated PC12 cells only following l‐DOPA exposure L Hondebrink, J Meulenbelt, JG Timmerman, M Van Den Berg, ... Journal of neurochemistry 111 (2), 624-633, 2009 | 15 | 2009 |
